Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Receives Average Recommendation of “Hold” from Brokerages

Shares of Aclaris Therapeutics, Inc. (NASDAQ:ACRS) have been given a consensus recommendation of “Hold” by the seven ratings firms that are presently covering the stock, MarketBeat Ratings reports. Six equities research analysts have rated the stock with a hold recommendation and one has given a buy recommendation to the company. The average 1-year price target among brokerages that have covered the stock in the last year is $22.25.

A number of analysts have commented on ACRS shares. Cantor Fitzgerald reiterated a “neutral” rating on shares of Aclaris Therapeutics in a research report on Friday, January 12th. BTIG Research reiterated a “neutral” rating on shares of Aclaris Therapeutics in a research report on Thursday, January 11th. StockNews.com downgraded Aclaris Therapeutics from a “hold” rating to a “sell” rating in a research report on Tuesday, April 2nd. Finally, HC Wainwright downgraded Aclaris Therapeutics from a “buy” rating to a “neutral” rating in a research report on Monday, January 22nd.

Institutional Investors Weigh In On Aclaris Therapeutics

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Zurcher Kantonalbank Zurich Cantonalbank increased its holdings in Aclaris Therapeutics by 42.6% during the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 20,317 shares of the biotechnology company’s stock valued at $139,000 after purchasing an additional 6,074 shares in the last quarter. Corton Capital Inc. acquired a new stake in Aclaris Therapeutics during the 3rd quarter valued at $102,000. Vontobel Holding Ltd. increased its holdings in Aclaris Therapeutics by 128.8% during the 4th quarter. Vontobel Holding Ltd. now owns 30,268 shares of the biotechnology company’s stock valued at $32,000 after purchasing an additional 17,040 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank increased its holdings in Aclaris Therapeutics by 115.5% during the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 43,784 shares of the biotechnology company’s stock valued at $46,000 after purchasing an additional 23,467 shares in the last quarter. Finally, BNP Paribas Financial Markets increased its holdings in Aclaris Therapeutics by 10.9% during the 1st quarter. BNP Paribas Financial Markets now owns 241,101 shares of the biotechnology company’s stock valued at $299,000 after purchasing an additional 23,747 shares in the last quarter. 98.34% of the stock is owned by institutional investors and hedge funds.

Aclaris Therapeutics Stock Up 4.0 %

Shares of NASDAQ:ACRS opened at $1.31 on Friday. The business has a 50 day moving average price of $1.22 and a 200 day moving average price of $1.67. Aclaris Therapeutics has a twelve month low of $0.59 and a twelve month high of $11.12. The company has a market cap of $93.35 million, a price-to-earnings ratio of -1.03 and a beta of 0.23.

Aclaris Therapeutics (NASDAQ:ACRS) last announced its quarterly earnings data on Tuesday, February 27th. The biotechnology company reported ($0.30) EPS for the quarter, topping analysts’ consensus estimates of ($0.37) by $0.07. Aclaris Therapeutics had a negative return on equity of 64.56% and a negative net margin of 283.15%. The company had revenue of $17.57 million during the quarter, compared to the consensus estimate of $3.96 million. Analysts anticipate that Aclaris Therapeutics will post -0.98 EPS for the current year.

About Aclaris Therapeutics

Aclaris Therapeutics, Inc a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States. The company operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing therapies to address significant unmet needs for immuno-inflammatory diseases.